Eesti -
eesti -
Ravimiamet
dasatinib sandoz õhukese polümeerikattega tablett
sandoz pharmaceuticals d.d. - dasatiniib - õhukese polümeerikattega tablett - 100mg 30tk; 100mg 10tk
Eesti -
eesti -
Ravimiamet
dasatinib teva õhukese polümeerikattega tablett
teva b.v. - dasatiniib - õhukese polümeerikattega tablett - 50mg 60tk; 50mg 56tk
Eesti -
eesti -
Ravimiamet
dasatinib sandoz õhukese polümeerikattega tablett
sandoz pharmaceuticals d.d. - dasatiniib - õhukese polümeerikattega tablett - 140mg 30tk; 140mg 10tk
Euroopa Liit -
eesti -
EMA (European Medicines Agency)
lenalidomide krka d.d.
krka, d.d., novo mesto - lenalidomide hydrochloride hydrate - multiple myeloma; lymphoma, follicular; myelodysplastic syndromes - immunosupressandid - multiple myelomalenalidomide krka d. as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) on näidustatud ravi täiskasvanud patsientidel, kellel on varem ravimata hulgimüeloom, kes ei ole abikõlblikud siirdamist. lenalidomide krka d. in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka d. as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. follicular lymphomalenalidomide krka d. in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).
Euroopa Liit -
eesti -
EMA (European Medicines Agency)
imcivree
rhythm pharmaceuticals netherlands b.v. - setmelanotide - rasvumine - antiobesioonipreparaadid, va dieedi tooted - imcivree is indicated for the treatment of obesity and the control of hunger associated with genetically confirmed bardet biedl syndrome (bbs), loss-of-function biallelic pro-opiomelanocortin (pomc), including pcsk1, deficiency or biallelic leptin receptor (lepr) deficiency in adults and children 6 years of age and above.
Euroopa Liit -
eesti -
EMA (European Medicines Agency)
voxzogo
biomarin international limited - vosoritide - achondroplasia - narkootikumid luuhaiguste raviks - voxzogo is indicated for the treatment of achondroplasia in patients 4 months of age and older whose epiphyses are not closed. the diagnosis of achondroplasia should be confirmed by appropriate genetic testing.